Weighing the evidence for pharmacological treatment interventions in mild COPD; A narrative perspective

Dave Singh, Anthony D. D'Urzo, James F. Donohue, Edward M. Kerwin

Research output: Contribution to journalReview articlepeer-review


There is increasing focus on understanding the nature of chronic obstructive pulmonary disease (COPD) during the earlier stages. Mild COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 1 or the now-withdrawn GOLD stage 0) represents an early stage of COPD that may progress to more severe disease. This review summarises the disease burden of patients with mild COPD and discusses the evidence for treatment intervention in this subgroup. Overall, patients with mild COPD suffer a substantial disease burden that includes persistent or potentially debilitating symptoms, increased risk of exacerbations, increased healthcare utilisation, reduced exercise tolerance and physical activity, and a higher rate of lung function decline versus controls. However, the evidence for treatment efficacy in these patients is limited due to their frequent exclusion from clinical trials. Careful assessment of disease burden and the rate of disease progression in individual patients, rather than a reliance on spirometry data, may identify patients who could benefit from earlier treatment intervention.

Original languageEnglish
Article number1108
JournalRespiratory research
Issue number1
Publication statusPublished - 8 Jul 2019


  • Chronic obstructive pulmonary disease
  • Corticosteroid
  • Early intervention


Dive into the research topics of 'Weighing the evidence for pharmacological treatment interventions in mild COPD; A narrative perspective'. Together they form a unique fingerprint.

Cite this